Breaking News

Takeda and TiGenix Enter into Licensing Agreement

Involves ex-U.S. rights to Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Takeda and TiGenix have entered into an exclusive ex-U.S. license, development and commercialization agreement for Cx601, a suspension of allogeneic adipose-derived stem cells (eASC) injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn’s disease. TiGenix will receive an upfront cash payment of €25 million. TiGenix will be eligible to receive additional regulatory and sales milestone payments for up to a potential total of €355 million and double-d...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters